Mostrar el registro sencillo del ítem

dc.contributor.authorVilaboa, Nuria
dc.contributor.authorLopez, Juan Antonio
dc.contributor.authorde Mesa, Marco
dc.contributor.authorEscudero-Duch, Clara
dc.contributor.authorWinfield, Natalie
dc.contributor.authorBayford, Melanie
dc.contributor.authorVoellmy, Richard
dc.date.accessioned2023-07-17T10:17:58Z
dc.date.available2023-07-17T10:17:58Z
dc.date.issued2023-04-19
dc.identifier.citationPharmaceuticals (Basel). 2023 Apr 19;16(4):616es_ES
dc.identifier.issn1424-8247es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16264
dc.description.abstractExposure of many cancer cells, including multiple myeloma cells, to cytotoxic concentrations of natural products celastrol and withaferin A or synthetic compounds of the IHSF series resulted in denaturation of a luciferase reporter protein. Proteomic analysis of detergent-insoluble extract fractions from HeLa-derived cells revealed that withaferin A, IHSF058 and IHSF115 caused denaturation of 915, 722 and 991 of 5132 detected cellular proteins, respectively, of which 440 were targeted by all three compounds. Western blots showed that important fractions of these proteins, in some cases approaching half of total protein amounts, unfolded. Relatively indiscriminate covalent modification of target proteins was observed; 1178 different proteins were modified by IHSF058. Further illustrating the depth of the induced proteostasis crisis, only 13% of these proteins detectably aggregated, and 79% of the proteins that aggregated were not targets of covalent modification. Numerous proteostasis network components were modified and/or found in aggregates. Proteostasis disruption caused by the study compounds may be more profound than that mediated by proteasome inhibitors. The compounds act by a different mechanism that may be less susceptible to resistance development. Multiple myeloma cells were particularly sensitive to the compounds. Development of an additional proteostasis-disrupting therapy of multiple myeloma is suggested.es_ES
dc.description.sponsorshipThis research was funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, grant numbers PID2021-126325OB-I00 and RTI2018-095159-B-I00, by MCIN/AEI/10.13039/501100011033, grant number RED2018-102626-T, by the Autonomous Community of Madrid, Spain, grant P2022/BMD-7406 and Program I2 (to N.V.), and by HSF Pharmaceuticals SA. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033).es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleDisruption of Proteostasis by Natural Products and Synthetic Compounds That Induce Pervasive Unfolding of Proteins: Therapeutic Implications.es_ES
dc.typeresearch articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID37111374es_ES
dc.format.volume16es_ES
dc.format.number4es_ES
dc.identifier.doi10.3390/ph16040616es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderFundación ProCNIC es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/ph16040616es_ES
dc.identifier.journalPharmaceuticals (Basel, Switzerland)es_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Proteómica / Metabolómicaes_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2021-126325OB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RTI2018-095159-B-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RED2018-102626-Tes_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/P2022/BMD-7406es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CEX2020-001041-Ses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional